Dr. Zarrinmayeh has 25 years of experience in the fields of medicinal chemistry and drug discovery. Dr. Zarrinmayeh has executed drug discovery research at the Lilly Research Laboratories of Eli Lilly Pharmaceuticals. During her tenure at Lilly, she made substantial contributions to the drug discovery programs that delivered clinical candidates for treatment of cancer and Central Nervous System (CNS) disorders. Her contributions to drug discovery in neuroscience field yielded several clinical candidates.
At the Indiana University School of Medicine, Radiology and Imaging Sciences Department, she has contributed to the discovery of novel PET radiotracer for evaluation of neuroinflammation in neurodegenerative diseases including Alzheimer’s disease (AD). Additionally, Dr. Zarrinmayeh has been engaged in fabrication of targeted multifunctional lipid-polymer hybrid nanoparticles (LPNPs) for application of intranasal delivery of oncolytic agents to the Glioblastoma multiforme (GBM) site in the brain.